Childhood Schistosomiasis: a Novel Strategy Extending the Benefits/Reach of Antihelminthic Treatment

Learn more about:
Related Clinical Trial
Retrospective Study of Clinical Practice and Management of Imported Schistosomiasis in France Monitoring Schistosome Hybrids Under Under Praziquantel Pressure Selexipag for the Treatment of Schistosomiasis-Associated Pulmonary Arterial Hypertension Correlating Protection Against Malaria With Serum Profiles Against Plasmodium Falciparum Antigen Repertoires Prevalence of Chronic Kidney Disease (CKD) and Risk Factors in Sub-Saharan Africa S. Japonicum and Pregnancy Outcomes Artemisinin-based Combination Therapy-Intermittent Preventive Treatment (ACT-IPT) Trial Among Schoolchildren in Kassena-Nankana, Ghana Study of Safety and Immune Response of the Sm14 Vaccine in Adults of Endemic Regions L-praziquantel Orodispersible Tablets (L-PZQ ODT) in Schistosoma Infected Children The Effect of Praziquantel Treatment on Schistosoma Mansoni Morbidity and re-Infection Along Lake Victoria, Uganda Praziquantel in Children Under Age 4 Schistosoma Haematobium Infections and Praziquantel Antioxidant Supplements in the Reversal of Schistosomal Peri-portal Fibrosis Single-sex Controlled Human Schistosomiasis Infection: Safety and Dose Finding A Phase Ib Study of the Safety, Reactogenicity, and Immunogenicity of Sm-TSP-2/Alhydrogel)(R) With or Without AP 10-701 for Intestinal Schistosomiasis in Healthy Exposed Adults Single-sex Female Controlled Human Schistosomiasis Mansoni Infection An Open Label Dose Finding Safety and Efficacy in Children and Infants Infected With Schistosomiasis (S.Mansoni) Schistosomiasis Effect on Response to Vaccines, Anaemia and Nutritional Status of Children of Northern Senegal Praziquantel-Pharmacokinetic Study Schistosomiasis in Women of Reproductive Age in Burkina Faso: Implications for Control Iron Supplementation in Schistosomiasis and Soil Transmitted Helminths Control Programmes in Zambia Schistosomiasis in Formal and Non-Formal Schools in Uganda: Implications for Control Programmes Using Community-Based Volunteers to Reach Non-Enrolled School Aged Children Through Community-Directed Treatment of Schistosomiasis in School-Aged Children in Rural Northern Ghana Sm-TSP-2 Schistosomiasis Vaccine in Healthy Ugandan Adults Clinical Trial of Bilhvax,a Vaccine Candidate Against Schistosomiasis A Phase I Study of the Safety, Reactogenicity, and Immunogenicity of Sm-TSP-2/Alhydrogel® With or Without GLA-AF for Intestinal Schistosomiasis in Healthy Adults Treatment of Female Genital Schistosomiasis (FGS) With Praziquantel: A Proof-of-Concept Study Schistosomiasis in Senegal Repeated Doses of Praziquantel in Schistosomiasis Treatment (RePST) Childhood Schistosomiasis: a Novel Strategy Extending the Benefits/Reach of Antihelminthic Treatment Anti-Schistosomiasis Vaccine: Sm14 Phase 2b-Sn in School Children Study to Evaluate the Safety of the Vaccine Prepared sm14 Against Schistosomiasis Arachidonic Acid Treatment Against Schistosomiasis Infection in Children Detection of Schistosomiasis CAA in Travellers After High-risk Water Contact Evaluation of Strategies for Improved Uptake of Preventive Treatment for Intestinal Schistosomiasis Health Benefits of Repeated Treatment in Pediatric Schistosomiasis Seropositivity and Adverse Birth Events in Migrants From Bilharzia-endemic Areas Women and Children as the Focus for Control of Schistosomiasis Infections in the Irrigations Area of Burkina Faso

Brief Title

Childhood Schistosomiasis: a Novel Strategy Extending the Benefits/Reach of Antihelminthic Treatment

Official Title

Childhood Schistosomiasis: a Novel Strategy Extending the Benefits/Reach of Antihelminthic Treatment

Brief Summary

      Objective and Hypotheses: This project has the overall objective of implementing and
      evaluating new approaches to reducing the current and future burden of urinary
      schistosomiasis in young children using the antihelminthic drug Praziquantel. The project
      aims to (1) determine the operational health benefits of treating schistosome infections
      early on re-infection and morbidity reduction, (2) determine if gut or urine microbiome
      structure (species diversity or abundance) is a risk factor for S. haematobium infection or
      morbidity, and (3) elucidate the factors and underlying mechanisms mediating the
      reduction/reversal of schistosome-related morbidity and resistance against
      infection/re-infection in young children.

Detailed Description

      This study aims to refine current paediatric treatment of schistosomiasis using the drug
      Praziquantel (PZQ) to improve the current and future health of pre-school children and
      infants. Praziquantel is cheap, highly efficacious and safe, presenting a realistic
      opportunity of using a pre-existing tool in a modified way to benefit child health and
      development. The study will focus on children aged 3 to 5 years of age, comparing the impact
      of early vs. later treatment with PZQ on the current and future health status of the
      children. By killing worms PZQ stops the morbidity related to the presence of worms and eggs
      such as anaemia, abdominal pain, diarrhoea and blood in the urine as well as induced immune
      responses associated with reduced re-infection rates. Therefore the study will investigate
      the immediate health benefits of treating pre-school children and infants and the effects of
      treatment on re-infection rates.

Study Type


Primary Outcome

Re-infection rates in children treated upon first infection compared to re-infection rates in children treated within 12 months of infection.

Secondary Outcome

 Change in immune measures (cytokine and antibody levels) following curative treatment




* Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.

Recruitment Information

Estimated Enrollment


Start Date

February 2016

Completion Date

February 27, 2018

Primary Completion Date

January 2018

Eligibility Criteria

        Inclusion Criteria:

          1. lifelong residents of the area

          2. have provided at least 2 urine and 2 stool for parasitological examination

          3. have given a blood sample before and after each treatment episode

          4. be negative for schistosomes, hookworm, Trichuris and Ascaris

          5. have frequent contact with infective water

        Exclusion Criteria:

          1. clinical signs of tuberculosis or malaria

          2. presenting with fever

          3. have had a recent major operation, illness or vaccination

          4. have previously received antihelminthic treatment

          5. are infected with any helminths




3 Years - 5 Years

Accepts Healthy Volunteers

Accepts Healthy Volunteers


Francisca Mutapi, PhD, , 

Location Countries


Location Countries


Administrative Informations



Organization ID


Responsible Party


Study Sponsor

University of Edinburgh


 University of Zimbabwe

Study Sponsor

Francisca Mutapi, PhD, Principal Investigator, University of Edinburgh

Verification Date

October 2018